ClinicalTrials.gg
Not yet recruitingNCT07947654PRECISION-MASLUpdated Nov 19, 2026

Precision Exercise Using Myostatin/Follistatin Ratio in Obese Adults

An interventional study of Supervised Progressive Resistance Training and Standard Lifestyle Advice in Sarcopenic Obesity, Obesity & Overweight and Insulin Resistance Syndrome, sponsored by Diabetes Foundation, India. Not yet recruiting at 1 site in India. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Diabetes Foundation, India · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 78 studies in Obesity with a site in India — 25 open to participants now, 32 under way, 23 of them phase 3. Obesity · India.

Planned enrollment
47th of 69
200 · median 731
Started
2026
with 18 others
No phase
20 of 78
5 open now
Primary completion
2029-11
later than 28 of 31 live
Registered
74th of 78
by date
Lead sponsor
4 of 78
Diabetes Foundation, India

Among the 78 studies in Obesity with a site in India, this one is the 47th largest by planned enrollment of the 69 interventional ones that give a count, is one of 19 that started in 2026, is one of 20 with no phase, reaches primary completion later than 28 of the 31 other live ones, and was the 74th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

25 of the 78 studies in Obesity with a site in India are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 35 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Obesity with a site in India, or all of them as a file.
02

Study summary

This study evaluates whether a 12-month supervised progressive resistance training program improves lean body mass and metabolic health in obese North Indian adults aged 35-60 years. Asian Indians are uniquely predisposed to sarcopenic obesity-the coexistence of excess body fat and reduced muscle mass-which significantly increases the risk of type 2 diabetes and cardiovascular disease.

Participants will be stratified into High-Ratio and Low-Ratio groups based on their baseline Myostatin/Follistatin (MSTN/FST) ratio, an biological index of muscle catabolism versus growth. Half of the participants in each stratum will undergo a 12-month supervised resistance training program, while the other half will receive standard lifestyle advice. The primary goal is to determine whether baseline MSTN/FST ratio predicts the extent of muscle mass gain and whether reducing this ratio mediates improvements in insulin resistance and systemic inflammation.

Read the detailed description

Background \& Scientific Rationale: Sarcopenic obesity is a major driver of cardiometabolic risk in Asian Indians due to low baseline lean mass combined with high visceral adiposity. Myostatin (MSTN) acts as a primary negative regulator of muscle growth, whereas follistatin (FST) acts as its circulating antagonist. Previous genetic research demonstrates that gain-of-function Myostatin gene variants are strongly associated with lower lean body mass and increased adiposity in North Indians. This trial prospectively tests whether the serum MSTN/FST ratio functions as a precision biomarker to stratify exercise response and guide targeted exercise interventions.

Study Objectives:

Determine the efficacy of a 12-month supervised resistance training program on total lean body mass (LBM) and physical performance compared to lifestyle control, testing for treatment interaction across baseline MSTN/FST strata.

Characterize the molecular adaptations of the myostatin axis by measuring serum myostatin, follistatin, MSTN/FST ratio, and peripheral blood mononuclear cell (PBMC) MSTN mRNA expression at baseline and 12 months.

Assess whether reductions in the MSTN/FST ratio mediate improvements in insulin resistance (HOMA-IR), systemic inflammatory markers (IL-6, TNF-α, hsCRP), and muscle quality.

Trial Design \& Interventions: A single-center, ratio-stratified, 1:1 parallel-group randomized controlled superiority trial of 200 obese North Indian adults.

Resistance Training Arm (n=100): 3 supervised sessions per week (60 minutes per session) at 70-80% 1-repetition maximum (1RM) using progressive resistance overload reassessed every 8 weeks.

Control Arm (n=100): Standard individualized dietary and physical activity advice per national guidelines without supervised exercise sessions.

Outcome Assessments: Dual-energy X-ray absorptiometry (DEXA) for total LBM, appendicular lean mass, and body fat percentage; handgrip dynamometry and 1RM testing for strength; quantitative ELISA for serum biomarkers; real-time qRT-PCR (2-ΔΔCt method) for PBMC MSTN mRNA expression; and standardized biochemical panels for glycemic and inflammatory profiles.

03

Conditions studied

  • Sarcopenic Obesity
  • Obesity & Overweight
  • Insulin Resistance Syndrome

Keywords

  • Sarcopenic obesity
  • Obesity
  • Insulin Resistance
  • Lean Muscle Mass
  • Asian Indians
  • Metabolic Health
04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 35-60 years inclusive
  • ≥ 25 kg/m² (Asian Indian cut-off for overweight)
  • Body fat percentage ≥ 30% in women or ≥ 25% in men measured by DEXA
  • Sedentary lifestyle, defined as less than 150 minutes per week of moderate-intensity physical activity by self-report and validated by wearable activity tracker at screening
  • Non-diabetic (fasting plasma glucose \< 126 mg/dL and \< 6.5%)
  • Willing and able to provide written
  • Resident within 25 km of Fortis C-DOC for the full 12-month trial duration

Exclusion criteria

Exclusion Criteria:

  • Known Type 2 Diabetes Mellitus
  • Established cardiovascular disease, heart failure, cerebrovascular accident, or peripheral arterial disease
  • Chronic kidney disease
  • Active or history of malignancy within 5 years
  • Use of anabolic steroids, systemic , growth hormone, or within 3 months of enrolment
  • Any musculoskeletal, neurological, or orthopaedic condition precluding participation in supervised resistance training
  • Pregnancy or lactation
  • Participation in any structured supervised exercise programme in the preceding 6 months
  • infection or other active chronic infection
  • Thyroid disorder not on stable replacement therapy for at least 3 months
  • Severe end-organ damage
  • Inability to provide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Progressive Resistance Training

    Supervised progressive resistance training program consisting of 3 sessions per week for 12 months (60 minutes per session) at 70-80% 1-repetition maximum (1RM). Includes multi-joint upper and lower body exercises (leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest/overhead press, crunches) with formal load reassessment every 8 weeks.

    Behavioral: Supervised Progressive Resistance Training · Behavioral: Standard Lifestyle Advice

  • Active comparator
    Standard Lifestyle Advice

    A single structured 60-minute lifestyle counseling session at baseline providing individualized dietary advice and physical activity recommendations based on ICMR national guidelines for Asian Indians, along with educational materials and follow-up assessments at 6 and 12 months.

    Behavioral: Supervised Progressive Resistance Training · Behavioral: Standard Lifestyle Advice

Interventions

  • BehavioralSupervised Progressive Resistance Training

    12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.

  • BehavioralStandard Lifestyle Advice

    A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.

06

What researchers measure

Primary outcomes

  1. Percentage change in total lean body mass

    Percentage change in total lean body mass (LBM) from baseline to 6 and 12 months measured by DEXA, comparing the resistance training and control groups and assessing differences between High-Ratio and Low-Ratio MSTN/FST strata.

    Time frame: Baseline, 6 months, 12 months

  2. Change in Serum Myostatin Concentration

    Change in serum myostatin levels quantified in duplicate via validated sandwich ELISA (intra-assay CV \< 8%, inter-assay CV \< 10%).

    Time frame: Baseline, 12 months

  3. Change in Serum Follistatin Concentration

    Change in serum follistatin levels quantified in duplicate via validated sandwich ELISA

    Time frame: Baseline, 12 months

  4. Change in Serum Myostatin/Follistatin (MSTN/FST) Ratio

    Integrated dynamic index of anabolic-catabolic balance calculated as serum myostatin (pg/mL) divided by serum follistatin (pg/mL).

    Time frame: Baseline, 12 months

  5. Change in PBMC MSTN mRNA Expression

    Relative gene expression of myostatin mRNA isolated from Peripheral Blood Mononuclear Cells (PBMCs) and measured via real-time quantitative PCR using the Livak 2 -ΔΔCT method normalized to GAPDH.

    Time frame: Baseline, 12 months

  6. Change in Systemic Inflammatory Markers

    Quantification of circulating serum Interleukin-6 (IL-6; pg/mL), Tumor Necrosis Factor-alpha (TNF-α; pg/mL), and high-sensitivity C-Reactive Protein (hsCRP; mg/L) via high-sensitivity immunoassay methods.

    Time frame: Baseline, 6 months, 12 months

  7. Change in Skeletal Muscle Quality

    Evaluation of muscle quality calculated as DEXA-derived muscle mass relative to strength, combined with ultrasound assessment of quadriceps muscle thickness and echo intensity.

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Appendicular Lean Mass (ASMI)

    Measured by DEXA (kg/m²)

    Time frame: Baseline, 6-month, and 12-month.

  2. Handgrip Strength

    Measured using a calibrated hand dynamometer (kg)

    Time frame: Baseline, 6-month, and 12-month.

  3. Lower-Body Muscle Strength

    Measured by 1-repetition maximum (1RM) in leg press (kg)

    Time frame: Baseline, 6-month, and 12-month.

  4. Gait Speed

    Measured by 4-metre timed walk test (seconds or m/s)

    Time frame: Baseline, 6-month, and 12-month.

07

Study locations

1 site
  • Diabetes Foundation India
    New Delhi, National Capital Territory of Delhi 110016, India
    • Dr Surya Prakash Bhatt, PhD · Contactsuryabhat@gmail.com · 919810085720
    • Professor Anoop Misra, MD · Principal investigator
    • Dr Surya Prakash Bhatt, PhD · Sub investigator
08

References and documents

Publications

  • Helsen MM, van den Broeke MR, van de Wal RS, van de Berg WJ, van Meijgaard E, Davis CH, Li Y, Goodwin I. Elevation changes in Antarctica mainly determined by accumulation variability. Science. 2008 Jun 20;320(5883):1626-9. doi: 10.1126/science.1153894. Epub 2008 May 29. PubMed 18511656 ↗
  • Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Jain SK, Qadar Pasha MA. Association of the Myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in north India. PLoS One. 2012;7(8):e40977. doi: 10.1371/journal.pone.0040977. Epub 2012 Aug 20. PubMed 22916099 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.

Of 3,694 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 35 months is above that.

Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947654
Lead sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Dr Surya Prakash Bhatt, PhD
Contact
suryabhat@gmail.com
919810085720
Professor Anoop Misra, MD
principal investigator · Diabetes Foundation, India

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion